JJP Biologics is focused on developing innovative biological therapeutics that leverage companion diagnostics to enhance patient stratification and personalize treatment strategies. Their approach emphasizes the early selection of companion diagnostics, which are diagnostic tests that identify specific biomarkers associated with disease severity. This strategy not only improves the likelihood of therapeutic effectiveness but also minimizes unwanted side effects and reduces development costs. The company is advancing multiple preclinical programs, including JJP-1212, a potential first-in-class CD89 antagonist aimed at treating autoinflammatory diseases, and JJP-1008, a humanized HVEM checkpoint inhibitor for solid tumors.

The technologies employed by JJP Biologics center around the development of novel biologics that target critical immune pathways. Their lead program, JJP-1212, focuses on antagonizing the IgA receptor CD89 to mitigate inflammatory responses driven by IgA-mediated mechanisms, particularly in diseases characterized by neutrophilic pathology. Meanwhile, JJP-1008 aims to exploit the HVEM pathway in immuno-oncology, using HVEM expression as a companion biomarker to select patients for treatment. By integrating companion diagnostics into their therapeutic development, JJP Biologics seeks to optimize clinical trial designs and enhance patient outcomes, ultimately aiming to address unmet medical needs across various disease indications.

Poland

JJP Biologics is an innovative Polish biotechnology company developing novel biological therapies around established companion diagnostics.
Our range of programs are in early stage development and we are actively seeking to cooperate with investors and academics on new or existing projects.

JJP Biologics

Company Details